Top Markets
Coin of the day
Sienna Biopharmaceuticals, Inc. Sienna Biopharmaceuticals, Inc.

Sienna Biopharmaceuticals, Inc.

SNNAQ
Peringkat dalam Saham #42234
Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm... Sienna Biopharmaceuticals, Inc. was a clinical-stage biopharmaceutical firm dedicated to discovering and advancing pharmaceutical treatments across diverse therapeutic fields. Its primary focus involved crafting therapies within immunology and inflammation, specifically targeting particular tissue pathways, notably in the skin. Among its pipeline, SNA-120 stood out as a pioneering, first-in-class inhibitor of tropomyosin receptor kinase A, undergoing Phase IIb clinical evaluation for addressing psoriasis and its associated itching. Another key candidate, SNA-125, a topical dual Janus kinase 3 inhibitor, progressed through Phase I/II clinical studies for conditions like atopic dermatitis, psoriasis, and pruritus. Furthermore, Sienna was advancing SNA-001, a topical suspension incorporating silver particles, into pivotal clinical trials not only for acne treatment but also for diminishing light-colored hair, encompassing shades such as white, gray, blonde, light brown, and light red. Established in 2010 and based in Westlake Village, California, the company originally operated as Sienna Labs, Inc. before rebranding as Sienna Biopharmaceuticals, Inc. in February 2016. However, the firm faced significant financial challenges, initiating Chapter 11 bankruptcy proceedings on September 16, 2019, which subsequently converted to Chapter 7 liquidation on December 18, 2019.
Harga Saham
$0.0001
Terakhir disinkronkan: 2026-08-11
Kapitalisasi Pasar
$3.09K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Sienna Biopharmaceuticals, Inc. (SNNAQ)

Kategori

Laba untuk Sienna Biopharmaceuticals, Inc. (SNNAQ)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Sienna Biopharmaceuticals, Inc., laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Sienna Biopharmaceuticals, Inc. dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
$5.27B -
US
$1.95B -
NL
- -
CH
$3.01B -
BE
- -
KR